Completing the Moderna or Pfizer COVID-19 monovalent vaccine primary series protects children aged 3-5 and 3-4, respectively, against symptomatic SARS-CoV-2 infection for at least four months, according to a study in those ages released yesterday by the Centers for Disease Control and Prevention.